Clinicians who treat persons with Gaucher disease will soon be able to offer their patients the first oral treatment option for this condition to be approved in the U.S. The FDA recently approved miglustat (Zavesca, Actelion Pharmaceuticals) for the treatment of adult patients with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. Miglustat will be available to patients later this year.
State pharmacy boards are generally exempt from the provisions of the Health Insurance Portability and Accountability Act (HIPAA), according to the attorney representing the National Association of Boards of Pharmacy.
If pharmacies don't beef up their patient leaflets by 2006, FDA will pass regulations, instead of relying on the private sector, to get the job done
USP safety review column
Presenters at the 2003 NACDS Pharmacy & Technology Conference listen to speakers opinions on proposed Medicare Rx legislation.
Florida passes law prohibiting illegible prescriptions and palm pilots do away with handwritten orders
The growth of specialty pharmacies.
PharmEcology offers new services to help hospitals dispose of their hazardous drug waste.
FDA task force on drug counterfeiting will develop a report with recommendations on how to protect our drug supply.
An update on the prescription discount cards of the nine companies out there and CMS' proposed card program
Crestor (Rosuvastatin) is a new statin indicated for patients with high cholesterol and triglycerides.
Clinicians will soon be able to offer men with erectile dysfunction (ED) the first drug to be approved in five years for the treatment of this condition. The FDA recently approved vardenafil (Levitra, Bayer/GlaxoSmithKline), which will be available in pharmacies within the next several weeks.
New cough, cold, and sore throat products for upcoming season.
This installment covers the deadline for meeting electronic claim submission requirements in health care and Medicare.
Why pharmacists don't do a good job of detecting drug interactions and how this can be improved
PBMs launch partial fill programs using 5.1 and reaction from chains that have had lawsuits brought against them regarding partial fill Rxs
So the kids are off to college--what health supplies did they pack?
Advate for prevention and control of bleeding in people with hemophilia A.
Oncologists will soon be able to offer patients the first 5-HT3 receptor antagonist with an indication for delayed chemotherapy-induced nausea and vomiting (CINV). The FDA recently approved palonosetron (Aloxi, MGI Pharma/Helsinn Healthcare) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. Palonosetron will be available to patients within the next several weeks.
What happens when a patient can't pay for his Rxs?
Here's how to get more R.Ph.s to use their prescriptive authority, allowed in most states but lagging in practice
Three state pharmacy boards are adopting an on-line pharmacist licensure renewal program developed by the National Association of Boards of Pharmacy.
PhRMA supports requiring drugs to be pedigreed to prevent counterfeiting, while HDMA thinks there other ways to get this done
How do R.Ph.s feel about PBMs and other third-party payers they have to deal with day in and day out? Find out in this exclusive Drug Topics survey
Two drug error case studies are presented
JCAHO tightens screws on its infection control standards
Senate and House must reach compromise before Medicare drug benefit passes.
Public Citizen urges feds to regulate patient package inserts, while pharmacy groups argue that they should be left up to industry to take care of.
The American Foundation for Pharmaceutical Education launched a campaign to help recruit more pharmacists to teaching using grants totaling $12 million to fund fellowships for pharmacy faculty positions.
The frustration of waiting for callbacks